Thursday, April 21 Scientific Platform Sessions Meeting Schedule 3:30 p.m.–5:30 p.m. Scientific Platform Sessions S51: Clinical Trials in Multiple Sclerosis II 3:30 p.m. S51.001 Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study — Sven Schippling, Jeffrey Cohen, Alasdair Coles, D Alastair Compston, Edward Fox, Massimo Filippi, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, Frederik Barkhof, David Margolin, Karthinathan Thangavelu, Douglas Arnold 3:45 p.m. S51.002 Treatment-Naive Patients with Active RRMS Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS I Study — Douglas Arnold, Jeffrey Cohen, Alasdair Coles, D Alastair Compston, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Karthinathan Thangavelu, Anthony Traboulsee 4:00 p.m. S51.003 Treatment-Naive Patients with Highly Active RRMS Demonstrated Durable Efficacy with Alemtuzumab over 5 Years —Stephen Krieger, Barry Singer, Mark Freedman, Jan Lycke, Regina Berkovich, David Margolin, Karthinathan Thangavelu, Eva Havrdova 4:15 p.m. S51.004 Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study —Volker Limmroth, Gavin Giovannoni, Douglas Arnold, Jeffrey Cohen, Alasdair Coles, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Karthinathan Thangavelu, D Alastair Compston 4:30 p.m. S51.005 Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II —Edward Fox, Douglas Arnold, Jeffrey Cohen, Gavin Giovannoni, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, Volker Limmroth, David Margolin, Karthinathan Thangavelu, Alasdair Coles 4:45 p.m. S51.006 Time Course of Glatiramer Acetate Efficacy in Relapsing-Remitting Multiple Sclerosis Patients in the Glatiramer Acetate Low-Frequency Administration (GALA) Study —Mat Davis, Natalia Ashtamker, Joshua Steinerman, Volker Knappertz 5:00 p.m. S51.007 Brain Volume As a Predictor of Disability in Primary Progressive Multiple Sclerosis: Evidence from the INFORMS Trial —Jerry Wolinsky, Dieter Häring, Maria Pia Sormani, Fred Lublin, David Miller, Mark Freedman, Bruce Cree, Howard Weiner, Catherine Lubetzki, Hans-Peter Hartung, Xavier Montalban, Bernard Uitdehaag, Martin Merschhemke, Bingbing Li, Norman Putzki, Ludwig Kappos 5:15 p.m. S51.008 MRI Parameters As Predictors of Long- Term Disease Outcome Over 8 Years in RRMS Patients —Douglas Jeffery, Daniela Piani Meier, Davorka Tomic, Dieter Häring, Timothy Vollmer S52: Clinical Epilepsy, Genetics, and Devices 3:30 p.m. S52.001 Long-Term Outcome of Adults with Medically Intractable Mesial Temporal Lobe Seizures Treated with Responsive Neurostimulation —Paul Van Ness, Tara Crowder Skarpaas, Martha Morrell 3:45 p.m. S52.002 Effects of Low-Frequency Stimulation of Anterior Piriform Cortex on Kainate- Induced Seizures in Rats —Mohamad Koubeissi, Arezou Bayat, Mark Skopin, Mittilesh Siddu, Komei Tsuchiya, Sweta Joshi, Sahar Jahan, Phillip Connell 4:00 p.m. S52.003 Validation of the Smartphone Brain Scanner for the Detection of Epileptiform Discharges Among Epilepsy Outpatients in Bhutan —Erica McKenzie, Andrew Lim, Edward Leung, Andrew Cole, Rodrigo Zepeda Garcia, Alice Lam, Ronald Thibert, Esther Bui, Damber Nirola, Sonam Deki, Lhab Tshering, Liesly Lee, Sarah Clark, Joseph Cohen, Jo Mantia, Kate Brizzi, Sarah Wahlster, Tali Sorets, Mikkel Aagaard, Arkadiusz Stopczynski, Lars Hansen, Sydney Cash, Farrah Mateen 4:15 p.m. S52.004 Evaluating the Prevalence of Neurological Autoantibodies Among Patients with Epilepsy of Unknown Etiology: Ongoing Prospective Study — Divyanshu Dubey, Ryan Hays, Abdulradha Alqallaf, Matthew Freeman, Kevin Chen, Kan Ding, Mark Agostini, Steven Vernino 4:30 p.m. S52.005 Severe Epileptic Encephalopathy Is a Frequent Neurological Comorbidity of Children Affected by the MECP2 Duplication Syndrome —Danah Marafie, Rebecca Schultz, Daniel Glaze, Alica Goldman, Bernhard Suter 4:45 p.m. S52.006 Novel Knock-in Mouse Model of Genetic Atp1a3 Dysfunction —Ashley Helseth, Syed Adil, Molly Linabarger, Eric Arehart, Nina Fainberg, Deepu Singh, William Wetsel, Ute Hochgeschwender, Arsen Hunanyan, Mohamad Mikati 5:00 p.m. S52.007 Sleep Homeostasis and NREM Slow Wave Activity in Animal Models and Humans with Focal or Generalized Epilepsy —Rama Maganti, Eli Wallace, Jesse Pfammater, Samantha Wright, Melanie Boly, Benjamin Jones, Mensen Armand, Mathew Jones, Giulio Tononi 5:15 p.m. S52.008 Hand Postures in Primary and Secondary Generalized Tonic-Clonic Seizures: A New Semiological Feature —Jason Siegel, William Tatum S53: Infectious Disease 3:30 p.m. S53.001 VZV Neurovasculitis in the Setting of a Novel Adult-Onset Immunocompromised State with Autoantibodies to Interferon Alpha (anti-IFNα)—Rahila Ansari, Shivam Mittal, Zerbe Christa, Lindsey Rosen, Steven Holland, Robert Bonomo 3:45 p.m. S53.002 Post Infectious Neurological Manifestations of Acute Dengue Viral Fever - a Prospective Study from India —Devashish Ruikar, Sita Sattaluri, Mohandas Surath 4:00 p.m. S53.003 Survivors of Ebola Virus Disease Have Persistent Neurological Deficits —Lauren Bowen, Bryan Smith, Sally Steinbach, Bridgette Billioux, Angela Summers, Shila Azodi, Joan Ohayon, Matthew Schindler, Avindra Nath 4:15 p.m. S53.004 Neurocognitive Impairment of HIV Elite Controllers: Feature of Viral Suppression and Inflammation? —Nisha Bhatia, Evelyn Lee, Dietmar Fuchs, Magnus Gisslen, Henrik Zetterberg, Alex Russell, Barbara Shacklett, Richard Price, Serena Spudich 4:30 p.m. S53.005 Insulin Signaling Suppresses Virus Replication and Neuroinflammation in HIV/AIDS —Manmeet Mamik, Eugene Asahchop, Yu Zhu, Brienne McKenzie, William Branton, Christopher Power 4:45 p.m. S53.006 Neurologic Signs and Symptoms Frequently Manifest in Acute HIV Infection —Joanna Hellmuth, James Fletcher, Victor Valcour, Eugène Kroon, Jintanat Ananworanich, Jintana Intasan, Sukalaya Lerdlum, Jared Narvid, Mantana Pothisri, Isabel Allen, Shelly Krebs, Bonnie Slike, Peeriya Prueksakaew, Linda Jagodzinski, Suwanna Puttamaswin, Nittaya Phanuphak, Serena Spudich 5:00 p.m. S53.007 Association Between Influenza Vaccination and Development of Guillain-Barré Syndrome in Adults: A Vaccine Safety Datalink (VSD) and Vaccine Adverse Event Reporting System (VAERS) Study —Francisco Gomez, Mohammad El-Ghanem, Abu Nasar, Nizar Souayah 5:15 p.m. S53.008 Clinical, Biological and Radiological Characteristics of Patients with Rocky Mountain Spotted Fever Encephalitis — Michael Bradshaw, Kelsey Ivey, Francesca Bagnato, NgocHanh Vu, Sumit Pruthi, Karen Bloch 3:30 p.m.–5:30 p.m. S51 Clinical Trials in Multiple Sclerosis II S52 Clinical Epilepsy, Genetics, and Devices S53 Infectious Disease C224 Primer of Behavioral Neurology II Director: Maria Gorno Tempini, MD, PhD, San Francisco, CA C225 Neurology Update IV Director: Barney J. Stern, MD, FAAN, Baltimore, MD C226 Deep Brain Stimulation Management II Director: Jill L. Ostrem, MD, San Francisco, CA C227 Organize and Run a Successful Code Stroke System Director: Enrique C. Leira, MD, MS, FAAN, Iowa City, IA C228 Neuromuscular Junction Disorders II Director: Laura Marie Tormoehlen, MD, Indianapolis, IN C229 Hot Topics in Sleep Neurology II Director: Erik Kent St. Louis, MD, FAAN, Rochester, MN C230 Neurologic Complications of Medical and Surgical Therapies Director: Sara E. Hocker, MD, Rochester, MN C231 Non-Alzheimer’s Dementia II Director: Gil Dan Rabinovici, MD, San Francisco, CA C232 Hot Topics in Headaches and Related Disorders II Director: Peter Goadsby, MD, PhD, San Francisco, CA 5:30 p.m.–7:00 p.m. Closing Party Happy Hour 148 2016 AAN Annual Meeting Abstract Listing
New Date and Time: CLOSING PARTY HAPPY HOUR THURSDAY, APRIL 21 5:30 P.M.–7:00 P.M. Celebrate the end of a great meeting at a special early-evening happy hour event! • Enjoy music, drinks, and socializing with colleagues • Make plans to explore beautiful Vancouver afterwards
Change language